Hui-Li Wong

Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer

Thiru Prasanna, Rachel Wong, Timothy Price, Jeremy Shapiro, Jeanne Tie, Hui-Li Wong, Louise Nott, David Roder, Margaret Lee, Suzanne Kosmider, Azim Jalali, Matthew Burge, Robert Padbury, Guy Maddern, Scott Carruthers, James Moore, Michael Sorich, Christos S Karapetis, Peter Gibbs, Desmond Yip

Journal article  |  2021  |  CURRENT PROBLEMS IN CANCER

BACKGROUND: Resection of oligometastases improves survival in metastatic colorectal cancer (mCRC). It is unclear whether the benef..

Prognostic significance of postsurgery circulating tumorDNAin nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies

Jeanne Tie, Joshua D Cohen, Serigne N Lo, Yuxuan Wang, Lu Li, Michael Christie, Margaret Lee, Rachel Wong, Suzanne Kosmider, Iain Skinner, Hui Li Wong, Belinda Lee, Matthew E Burge, Desmond Yip, Christos S Karapetis, Timothy J Price, Niall C Tebbutt, Andrew M Haydon, Janine Ptak, Mary J Schaeffer, et al.

Journal article  |  2020  |  INTERNATIONAL JOURNAL OF CANCER

Studies in multiple solid tumor types have demonstrated the prognostic significance of ctDNA analysis after curative intent surger..

Circulating Tumour DNA to Guide Treatment of Gastrointestinal Malignancies

Yat Hang To, Belinda Lee, Hui-Li Wong, Peter Gibbs, Jeanne Tie

Journal article  |  2020  |  VISCERAL MEDICINE

Background: Gastrointestinal cancers are among the most common cancers worldwide and account for a high proportion of cancer-relat..

Real-world outcomes for neoadjuvant capecitabine versus infusional 5-fluorouracil in the treatment of locally advanced rectal cancer.

Matthew Loft, Hui-Li Wong, Suzanne Kosmider, Margaret Lee, Jeanne Tie, Rachel Wong, Ian Jones, Matthew Croxford, Malcolm Steel, Ian Faragher, Mario Guerrieri, Michael Christie, Peter Gibbs

Journal article  |  2020  |  JOURNAL OF CLINICAL ONCOLOGY

Background Neoadjuvant chemoradiation therapy (CRT) is standard of care treatment for locally advanced rectal cancer (LARC). A pat..

Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data

Koen Degeling, Hui-Li Wong, Hendrik Koffijberg, Azim Jalali, Jeremy Shapiro, Suzanne Kosmider, Rachel Wong, Belinda Lee, Matthew Burge, Jeanne Tie, Desmond Yip, Louise Nott, Adnan Khattak, Stephanie Lim, Susan Caird, Peter Gibbs, Maarten IJzerman

Journal article  |  2020  |  PHARMACOECONOMICS

BACKGROUND: Simulation models utilizing real-world data have potential to optimize treatment sequencing strategies for specific pa..

Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer

Wanyuan Cui, Fanny Franchini, Marliese Alexander, Ann Officer, Hui-Li Wong, Maarten IJzerman, Jayesh Desai, Benjamin J Solomon

Journal article  |  2020  |  LUNG CANCER

BACKGROUND: KRAS mutations are found in 20-30 % of non-small cell lung cancers (NSCLC) and were traditionally considered undruggab..

Assessing the significance of KRAS G12C mutation: Clinicopathologic features, treatments, and survival outcomes in a real-world KRAS mutant non-small cell lung cancer cohort.

Wanyuan Cui, Fanny Franchini, Marliese Alexander, Ann Officer, Hui Li Wong, Maarten J IJzerman, Jayesh Desai, Benjamin J Solomon

Conference Proceedings  |  2020  |  JOURNAL OF CLINICAL ONCOLOGY

e19324 Background: KRASG12C mutations are present in 15% of non-small cell lung cancer (NSCLC) and have recently been shown to co..

Assessing real-world outcomes in metastatic colorectal cancer with KRAS(G12C) mutation.

Hui-Li Wong, Wanyuan Cui, Matthew Loft, Margaret Lee, Rachel Wong, Jeremy David Shapiro, Jeanne Tie, Belinda Lee, Prasad Cooray, Allan Solomon Zimet, Peter Gibbs, Benjamin J Solomon, Jayesh Desai

Conference Proceedings  |  2020  |  JOURNAL OF CLINICAL ONCOLOGY

e16072 Background: The KRASG12C mutation is present in 3% of colorectal cancer and is of particular interest given the recent dev..

Clinical implications of assumptions in cost-effectiveness analyses of systemic therapies for metastatic colorectal cancer.

Koen Degeling, Martin Vu, Hendrik Koffijberg, Hui-Li Wong, Miriam Koopman, Peter Gibbs, Maarten J IJzerman

Conference Proceedings  |  2020  |  JOURNAL OF CLINICAL ONCOLOGY

e16021 Background: Considerable variation is observed in model-based cost-effectiveness analyses of systemic therapies for metast..

Health economic analysis of doublet chemotherapy with and without bevacizumab for first-line treatment of RAS mutant metastatic colorectal cancer based on real-world data.

Koen Degeling, Hui-Li Wong, Amanda Pereira-Salgado, Suzanne Kosmider, Rachel Wong, Jeanne Tie, Greg Stefanou, Louise M Nott, Jeremy David Shapiro, Gary Edward Richardson, Peter Gibbs, Maarten J IJzerman

Conference Proceedings  |  2020  |  JOURNAL OF CLINICAL ONCOLOGY

e16048 Background: Bevacizumab remains the dominant biologic treatment option for RAS mutant (RASmt) metastatic colorectal cancer..